Dermavant Prepares For First Launch, Looking To Build A Blockbuster Psoriasis Brand
Executive Summary
The Roivant-owned company's Vtama topical cream was approved by the US FDA with a broad label permitting use for mild, moderate or severe psoriasis.
You may also be interested in...
Keeping Track: US FDA Clears Vtama, But Not Bimekizumab Or Ycanth; Tibsovo Takes RTOR To Frontline AML Setting
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Dermavant's Tapinarof Could Bring Innovation To Topical Psoriasis Market
CEO Todd Zavodnick said the non-steroidal topical cream is poised to become a blockbuster brand.
$3bn Roivant Deal To Fill Holes At Dainippon
Facing looming expiries for its top product, Japan’s Sumitomo Dainippon is planning to acquire multiple "vant" companies and their portfolios of clinical stage assets from Roivant, in a move to address mid-term challenges to revenues and following recent late-stage development failures.